Precipio, Inc. (NASDAQ:PRPO) tinted gains of +6.96% (+0.03 points) to US$0.43. The volume of 1.93 Million shares climbed up over an trading activity of 1.65 Million shares. EPS ratio determined by looking at last 12 month figures is -19.33. Over the same time span, the stock marked US$28.16 as its best level and the lowest price reached was US$0.36. The corporation has a market cap of US$5.53 Million.
Precipio, Inc. (NASDAQ:PRPO)’s earnings per share has been growing at a 31.7 percent rate over the past 5 year when average revenue increase was noted as -44.1 percent. The return on equity ratio or ROE stands at -407.4 percent while most common profitability ratio return on investment (ROI) was -105.2 percent. The company’s institutional ownership is monitored at 7.4 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 16.9 percent gross margin.
Cytosorbents Corporation (NASDAQ:CTSO) is worth US$299.49 Million and has recently risen 6.91% to US$10.05. The latest exchange of 0.79 Million shares is below its average trading activity of 218.78 Million shares. The day began at US$8.85 but the price moved to US$8.85 at one point during the trading and finally capitulating to a session high of US$9.5. The stock tapped a 52-week high of US$9.8 while the mean 12-month price target for the shares is US$12.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 20.51, and a price to sales ratio of 17.62. For the past 5 years, the company’s revenue has grown 62.4%, while the company’s earnings per share has grown 16.4%. With an institutional ownership near 10.6%, it carries an earnings per share ratio of -0.35.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.